Micronutrient monitoring: which panel, how often, and on whose evidence

Micronutrient monitoring on this drug class is conducted almost entirely on borrowed authority. The schedules in circulation — iron studies, B12 and folate, vitamin D, sometimes thiamine and zinc, at three, six and twelve months — are adapted from post-bariatric surveillance protocols. Those protocols exist because bariatric procedures alter gastrointestinal anatomy, reduce acid secretion, bypass the duodenum and impair the absorption of specific nutrients by identified mechanisms. None of that applies to a receptor agonist.

Thyroid function during energy restriction

Sustained energy restriction produces a characteristic and benign change in thyroid function tests: triiodothyronine falls, reverse triiodothyronine rises, thyroxine changes little and thyroid-stimulating hormone falls modestly or remains unchanged. This is the low-T3 pattern of adaptation to reduced energy availability, it is not hypothyroidism, and treating it as such is an error that predates this drug class by decades.

The relevant point for monitoring is that a thyroid panel drawn during rapid weight loss will frequently show a low or low-normal free T3, and that this does not indicate thyroid disease, does not require treatment, and reverses when energy balance is restored. Thyroid-stimulating hormone remains the appropriate first-line test for suspected thyroid dysfunction; adding free T3 to a panel during active weight loss reliably generates a result that requires explaining.

Separately and unrelatedly, this class carries a boxed warning in some jurisdictions derived from rodent thyroid C-cell findings. Serum calcitonin monitoring is not recommended for that purpose, and pharmacoepidemiological work examining thyroid cancer incidence in treated populations has not established the association the rodent data raised as a possibility.¹ The Journal reports the boxed warning as what it is: a precaution derived from a rodent finding whose human relevance remains unestablished.

The bariatric schedule and how far it transfers

Post-bariatric micronutrient surveillance is well founded and specific. Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, which are the principal absorption sites for iron, calcium and several B vitamins; reduced gastric acid impairs the release of food-bound B12 and the reduction of ferric iron; and the intrinsic-factor pathway is compromised by the reduction in parietal cell mass. Each of those is an identified mechanism supporting a specific test at a specific interval.

None of them applies to a receptor agonist. The gastrointestinal tract is anatomically intact, acid secretion is broadly preserved, and no absorption site is bypassed. The mechanism that does apply is reduced intake, which predicts deficiency in proportion to dietary inadequacy rather than in the bariatric pattern. Those two predictions differ: a person eating half as much of a varied diet is at different risk from a person whose duodenum has been bypassed, and the appropriate surveillance is not obviously the same.

The Journal has looked for a cohort study characterising micronutrient status in this population at twelve months or beyond and has not found one. Until one exists, monitoring schedules for this drug class are precautionary extrapolation. That is a defensible thing to do and it should be described accurately rather than presented as protocol.

Four markers with specific confounders

Vitamin D. Concentrations frequently rise during weight loss for a reason unrelated to intake: the vitamin is fat-soluble and distributes into adipose tissue, so a smaller adipose compartment produces a higher serum concentration at unchanged total body content. A rising 25-hydroxyvitamin D during weight loss is therefore a volume-of-distribution effect as much as anything else.

Vitamin B12. The commonest confounder is co-prescription of metformin, which lowers B12 by a well-established mechanism, in a population where metformin is extremely common. Attributing a low B12 to reduced intake when the person has been on metformin for eight years is a sequencing error rather than a laboratory one.

Thiamine. The one micronutrient where the Journal thinks the precaution is well founded on mechanism: thiamine stores are small, turnover is rapid, and protracted vomiting is a recognised precipitant of deficiency. Prolonged vomiting during escalation is a plausible route to it.

Magnesium and potassium. Both fall with persistent vomiting and both are genuine findings when they do. Neither is a nutritional marker in that context; they are consequences of the losses.

How the Journal reports a laboratory figure

Five things accompany a laboratory number in these pages. The units, because international and conventional units differ for several analytes and the same value means different things in each. The reference interval used, with a note where the interval is contested, as it is for alanine aminotransferase. The baseline, because a change of 1.8 percentage points in HbA1c from a starting value of 8.3 is a different claim from the same change from 9.5. The estimand where the figure comes from a trial. And the reference change value where we are discussing an individual delta rather than a group mean.

We also state the assay method where it matters, which is more often than one would like: HbA1c in the presence of a haemoglobin variant, thyroid function in the presence of interfering antibodies, and creatinine measured by enzymatic against Jaffe methods all behave differently, and a comparison across methods is not a comparison.

This is a heavier apparatus than most publications carry and it exists because the alternative, in our experience, is a stream of technically accurate figures that lead readers to conclusions the data does not support. Errors in this apparatus should be reported to standards@compoundjournal.com; the correction log records what came of each one.

What this department is for

The Laboratory Notebook reports what tests measure, how they behave, and what has been found using them. It does not recommend monitoring schedules, interpret readers’ results, or advise on treatment. A laboratory result belongs in a conversation with a clinician who has the rest of the picture, and this publication is emphatically not that conversation.

Two standing notes. Several compounds discussed in these pages are sold for research use only and are not approved for human use in any jurisdiction; the Journal reports on them as commodities and as analytical problems, not as therapies. And where we describe what the pivotal trials monitored, that is reporting on trial protocols and not a template anybody should adopt from a magazine.

Correspondence is welcome at letters@compoundjournal.com. The Journal receives a steady flow of letters containing readers’ own panel results with a request for interpretation, and we do not provide it — not from caution but because a panel without a history, an examination and a reason for ordering it cannot be interpreted by anybody, including us.

Readers who order their own panels privately, which a substantial fraction of this publication’s readership does, are in a specific position: they have the data and not the interpretive apparatus, and the apparatus is where the value is. The reference change value for the analyte in question, and the person’s own previous result, do more interpretive work than any reference interval on the printout.